KBRA Assigns Ratings to $499.3 Million RCKT Mortgage Trust 2025-CES12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Businesswire
- Transaction Size: RCKT Mortgage Trust 2025-CES12 is a $499.3 million RMBS transaction fully sponsored by Rocket Mortgage, LLC and its affiliate Woodward Capital Management LLC, indicating strong market demand for newly originated second lien mortgages.
- Loan Characteristics: The transaction consists of 5,485 newly originated closed-end second lien mortgages, with an average seasoning of less than one month, reflecting confidence and liquidity in the market for new loans.
- Interest Rate Structure: The mortgage pool features a diverse interest rate structure with fixed-rate loans of 4.0% for 10-year, 8.3% for 15-year, 65.0% for 20-year, and 22.6% for 30-year terms, catering to various borrower needs and enhancing market appeal.
- Rating Methodology: KBRA's rating approach involved loan-level analysis through its Residential Asset Loss Model (REALM), incorporating third-party due diligence results and cash flow modeling, ensuring the accuracy and reliability of the ratings, which bolsters market confidence in the transaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCKT
Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 8.63 USD with a low forecast of 5.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 3.550
Low
5.00
Averages
8.63
High
16.00
Current: 3.550
Low
5.00
Averages
8.63
High
16.00
About RCKT
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KBRA Assigns Ratings to $548.3 Million RCKT Mortgage Trust 2026-CES1
- Transaction Size: The RCKT 2026-CES1 mortgage trust has a transaction size of $548.3 million, consisting entirely of newly originated closed-end second lien mortgages issued by Rocket Mortgage, indicating sustained market demand for new loan products.
- Loan Characteristics: The trust's loan pool comprises 5,839 fully amortizing, fixed-rate mortgages with average terms of 10 years (4.1%), 15 years (7.8%), 20 years (62.7%), and 30 years (25.5%), reflecting a diverse range of loan term options.
- Rating Methodology: KBRA employs its Residential Asset Loss Model (REALM) for loan-level analysis of the mortgage pool, supplemented by third-party due diligence results and cash flow modeling analysis, ensuring the accuracy and reliability of the ratings, thereby enhancing market confidence.
- Legal Structure Review: During the rating process, KBRA also assessed the legal structure and documentation of the transaction, ensuring compliance of all key transaction parties, which reduces investment risk and increases investor trust.
Continue Reading
Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of α-Klotho in vascular health, providing scientific backing for its Klothonova therapy developed in partnership with Singapore's Austrianova, which is expected to enhance market acceptance of the therapy.
- Significant Market Potential: The precision medicine market is projected to grow from $119 billion in 2025 to $471 billion by 2034, and Avant's technological innovations align perfectly with this trend, positioning the company to capture a significant share of the future market.
- Deepened Strategic Collaboration: The exclusive global licensing agreement with Klothea Bio grants Klothonova rights to develop and commercialize Klotho-producing cells, leveraging Austrianova's technology, which is anticipated to accelerate the product's market entry.
- Diversified Investment Strategy: Avant is also collaborating with SGAustria to provide funding over the next eight months for diabetes treatment, demonstrating its strategic intent to expand across multiple therapeutic areas.
Continue Reading